The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
Other Relationship - Merck
A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
 
Maria-Victoria Mateos
Honoraria - Amgen; Celgene; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda
 
Hilary Blacklock
Consulting or Advisory Role - Celgene
 
Fredrik Schjesvold
Honoraria - Abbvie; Amgen; Celgene; Janssen; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Pfizer; Takeda
Research Funding - Amgen; Janssen
Travel, Accommodations, Expenses - Amgen; Celgene
 
Albert Oriol Rocafiguera
Consulting or Advisory Role - Amgen; Janssen; Takeda
Speakers' Bureau - Amgen; Janssen; Takeda
 
David Simpson
Honoraria - Abbvie; Celgene; Janssen-Cilag; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Abbvie; Celgene; Janssen-Cilag; Merck
Research Funding - Amgen
 
Anupkumar George
Consulting or Advisory Role - Celgene; Roche
Travel, Accommodations, Expenses - Celgene; Roche
 
Hartmut Goldschmidt
Honoraria - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen-Cilag; Novartis
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi; Takeda (Inst)
Speakers' Bureau - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma Europe; Janssen; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda
 
Alessandra Larocca
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag
 
Daniel Wayne Sherbenou
No Relationships to Disclose
 
Irit Avivi
No Relationships to Disclose
 
Shinsuke Iida
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Janssen; MSD; Ono Pharmaceutical; Sanofi; Takeda
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Chugai Pharma; Gilead Sciences; Janssen; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Takeda
 
Morio Matsumoto
No Relationships to Disclose
 
Saad Zafar Usmani
Consulting or Advisory Role - Amgen; Celgene; Janssen Oncology
Speakers' Bureau - Amgen; Celgene; Takeda
Research Funding - Array BioPharma; Celgene; Janssen Oncology; Millennium; Onyx; Pharmacyclics; Sanofi
 
Sundar Jagannath
Honoraria - Celgene; Karyopharm Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Novartis
Research Funding - Bristol-Myers Squibb (Inst); celgene (Inst); Karyopharm Therapeutics (Inst)
 
Paula Rodriguez-Otero
Consulting or Advisory Role - Celgene; Janssen; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Janssen
Research Funding - Bristol-Myers Squibb; Celgene
 
Uma Kher
No Relationships to Disclose
 
Mohammed Z.H. Farooqui
No Relationships to Disclose
 
Jason Liao
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Sagar Lonial
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Millennium; Novartis; Onyx